Iris Kuss

3.5k total citations · 2 hit papers
40 papers, 1.3k citations indexed

About

Iris Kuss is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Iris Kuss has authored 40 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Pulmonary and Respiratory Medicine, 21 papers in Radiology, Nuclear Medicine and Imaging and 19 papers in Oncology. Recurrent topics in Iris Kuss's work include Prostate Cancer Treatment and Research (32 papers), Radiopharmaceutical Chemistry and Applications (19 papers) and Cancer Treatment and Pharmacology (17 papers). Iris Kuss is often cited by papers focused on Prostate Cancer Treatment and Research (32 papers), Radiopharmaceutical Chemistry and Applications (19 papers) and Cancer Treatment and Pharmacology (17 papers). Iris Kuss collaborates with scholars based in Germany, United States and France. Iris Kuss's co-authors include Karim Fizazi, Neal D. Shore, Teuvo L.J. Tammela, Amir Snapir, Toni Sarapohja, Egils Vjaters, Mindaugas Jievaltas, B. Yа. Alekseev, Albertas Ulys and Murilo Luz and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Annals of Oncology.

In The Last Decade

Iris Kuss

39 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

2019 579 citations Karim Fizazi, Neal D. Shore et al. profile →
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial

2023 99 citations Maha Hussain, Bertrand Tombal et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Iris Kuss Germany	12	1.1k	400	400	251	224	40	1.3k
Murilo Luz Brazil	7	952 0.8×	303 0.8×	324 0.8×	199 0.8×	175 0.8×	34	1.1k
Albertas Ulys Lithuania	16	1.1k 1.0×	337 0.8×	459 1.1×	323 1.3×	235 1.0×	64	1.4k
Vahid Naini United States	8	1.1k 1.0×	417 1.0×	357 0.9×	244 1.0×	191 0.9×	21	1.2k
Sharon McCarthy United States	8	962 0.9×	341 0.9×	326 0.8×	217 0.9×	175 0.8×	28	1.1k
S. Polyakov Belarus	8	811 0.7×	273 0.7×	281 0.7×	180 0.7×	153 0.7×	20	940
Álvaro Juárez Soto Spain	8	1.1k 0.9×	379 0.9×	345 0.9×	222 0.9×	201 0.9×	44	1.2k
Andrea Juliana Gomes United States	8	1.4k 1.2×	496 1.2×	450 1.1×	336 1.3×	245 1.1×	24	1.5k
Youyi Shu United States	9	827 0.7×	263 0.7×	290 0.7×	176 0.7×	146 0.7×	14	1.0k
Kris Deprince United States	7	948 0.8×	333 0.8×	312 0.8×	252 1.0×	167 0.7×	15	1.2k
Angela Lopez‐Gitlitz United States	14	1.8k 1.6×	676 1.7×	587 1.5×	368 1.5×	297 1.3×	62	1.9k

Countries citing papers authored by Iris Kuss

Since Specialization

Citations

This map shows the geographic impact of Iris Kuss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Iris Kuss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Iris Kuss more than expected).

Fields of papers citing papers by Iris Kuss

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Iris Kuss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Iris Kuss. The network helps show where Iris Kuss may publish in the future.

Co-authorship network of co-authors of Iris Kuss

This figure shows the co-authorship network connecting the top 25 collaborators of Iris Kuss. A scholar is included among the top collaborators of Iris Kuss based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Iris Kuss. Iris Kuss is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Saad, Fred, Maha Hussain, Bertrand Tombal, et al.. (2024). Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study. European Urology. 86(4). 329–339. 18 indexed citations

Morgans, Alicia K., Juergen E. Gschwend, Neal D. Shore, et al.. (2023). 1841TiP Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase III, randomized, double-blind, placebo-controlled study (ARASTEP). Annals of Oncology. 34. S997–S998. 1 indexed citations

Williams, Steven, Ndaba Mazibuko, Owen O’Daly, et al.. (2023). Comparison of Cerebral Blood Flow in Regions Relevant to Cognition After Enzalutamide, Darolutamide, and Placebo in Healthy Volunteers: A Randomized Crossover Trial. Targeted Oncology. 18(3). 403–413. 9 indexed citations

Wang, Shanshan, Cheng Fu, Qing Zou, et al.. (2023). Efficacy and safety of darolutamide in Chinese patients with metastatic hormone-sensitive prostate cancer (mHSPC): A subpopulation analysis of the phase 3 ARASENS study.. Journal of Clinical Oncology. 41(16_suppl). e17076–e17076. 1 indexed citations

Shore, Neal D., Karim Fizazi, Teuvo L.J. Tammela, et al.. (2023). Effect of crossover from placebo to darolutamide on overall survival in men with non-metastatic prostate cancer: sensitivity analyses from the randomised phase 3 ARAMIS study. European Journal of Cancer. 195. 113342–113342.

Saad, Fred, Bertrand Tombal, Martin Boegemann, et al.. (2023). 1784P Prostate-specific antigen (PSA) outcomes with darolutamide (DARO): Androgen-deprivation therapy (ADT) and docetaxel (DOC) in patients (pts) with high- and low-volume metastatic hormone-sensitive prostate cancer (mHSPC) in ARASENS. Annals of Oncology. 34. S964–S964. 3 indexed citations

Hussain, Maha, Bertrand Tombal, Fred Saad, et al.. (2023). Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial. Journal of Clinical Oncology. 41(20). 3595–3607. 99 indexed citations breakdown →

Jones, Robert H., Karim Fizazi, Nicholas D. James, et al.. (2023). Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases. 27(4). 786–789. 1 indexed citations

Fizazi, Karim, Matthew Ryan Smith, Muhammad Hussain, et al.. (2022). 1360MO Quality of life and patient-relevant endpoints with darolutamide in the phase III ARASENS study. Annals of Oncology. 33. S1162–S1162. 4 indexed citations

10.

Jeffers, Michael, Christian Kappeler, Iris Kuss, et al.. (2022). Broad spectrum of regorafenib activity on mutant KIT and absence of clonal selection in gastrointestinal stromal tumor (GIST): correlative analysis from the GRID trial. Gastric Cancer. 25(3). 598–608. 5 indexed citations

11.

Vjaters, Egils, Karim Fizazi, Nicholas D. James, et al.. (2022). Long-term safety of darolutamide in patients with metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology. 40(6_suppl). 90–90. 1 indexed citations

12.

Smith, Matthew R., Neal D. Shore, Teuvo L.J. Tammela, et al.. (2021). Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial. European Journal of Cancer. 154. 138–146. 23 indexed citations

13.

Fizazi, Karim, Neal D. Shore, Matthew Smith, et al.. (2021). Darolutamide (DARO) tolerability from extended follow up and treatment response in the phase 3 ARAMIS trial.. Journal of Clinical Oncology. 39(15_suppl). 5079–5079. 4 indexed citations

14.

Fizazi, Karim, Neal D. Shore, Teuvo L.J. Tammela, et al.. (2020). 223P Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC). Annals of Oncology. 31. S1328–S1328. 2 indexed citations

15.

Fizazi, Karim, Neal D. Shore, Matthew R. Smith, et al.. (2020). 633P Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial. Annals of Oncology. 31. S522–S522. 2 indexed citations

16.

Shore, Neal D., Christian Zurth, Robert E. Fricke, et al.. (2019). Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial. Targeted Oncology. 14(5). 527–539. 66 indexed citations

17.

Tombal, Bertrand, Fred Saad, Maha Hussain, et al.. (2017). ARASENS: A phase 3 trial of darolutamide in males with metastatic hormone-sensitive prostate cancer (mHSPC). Annals of Oncology. 28. v291–v292. 1 indexed citations

18.

Komatsu, Yoshito, Toshihiko Doi, Akira Sawaki, et al.. (2015). Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial. International Journal of Clinical Oncology. 20(5). 905–912. 26 indexed citations

19.

Kang, Yoon‐Koo, Jianmin Xu, Yoshito Komatsu, et al.. (2013). Subgroup Analysis of Asian Patients in the Phase III Trial (GRID) of Regorafenib in Pretreated Metastatic GIST. Annals of Oncology. 24. ix6–ix6. 1 indexed citations

20.

Jonat, W., et al.. (2013). Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer. Annals of Oncology. 24(10). 2543–2548. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact